Brief: Argenx: FDA Accepts Priority Review sBLA for Vyvgart in Seronegative gMG
13/01/2026 06:03
Jan 13 (Reuters) - argenx SE ARGX.BR: ARGENX ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR VYVGART IN ACHR-AB SERONEGATIVE GMG APPLICATION HAS BEEN GRANTED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 10, 2026 Source text: nGNE3qdF54 Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles